PE20091628A1 - Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona - Google Patents

Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona

Info

Publication number
PE20091628A1
PE20091628A1 PE2009000395A PE2009000395A PE20091628A1 PE 20091628 A1 PE20091628 A1 PE 20091628A1 PE 2009000395 A PE2009000395 A PE 2009000395A PE 2009000395 A PE2009000395 A PE 2009000395A PE 20091628 A1 PE20091628 A1 PE 20091628A1
Authority
PE
Peru
Prior art keywords
benzimidazol
methylpiperazin
quinolin
fluoro
amino
Prior art date
Application number
PE2009000395A
Other languages
English (en)
Spanish (es)
Inventor
Danielle Giron
Philippe Piechon
Walter Hammerschmidt
Johanne Polasek
Andreas Schreiner
Frank Stowasser
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40622140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091628(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20091628A1 publication Critical patent/PE20091628A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2009000395A 2008-03-19 2009-03-17 Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona PE20091628A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3774608P 2008-03-19 2008-03-19

Publications (1)

Publication Number Publication Date
PE20091628A1 true PE20091628A1 (es) 2009-11-19

Family

ID=40622140

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000395A PE20091628A1 (es) 2008-03-19 2009-03-17 Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona

Country Status (25)

Country Link
US (1) US8563556B2 (zh)
EP (1) EP2257544B1 (zh)
JP (1) JP2011515370A (zh)
KR (1) KR20100137517A (zh)
CN (1) CN101970425B (zh)
AR (1) AR070924A1 (zh)
AU (1) AU2009227003B2 (zh)
BR (1) BRPI0909762A2 (zh)
CA (1) CA2718076A1 (zh)
CL (1) CL2009000651A1 (zh)
CO (1) CO6321253A2 (zh)
EC (1) ECSP10010555A (zh)
HK (1) HK1147492A1 (zh)
IL (1) IL208020A0 (zh)
MA (1) MA32230B1 (zh)
MX (1) MX2010010152A (zh)
MY (1) MY150554A (zh)
NZ (2) NZ600887A (zh)
PE (1) PE20091628A1 (zh)
PH (2) PH12012502569A1 (zh)
RU (1) RU2497820C2 (zh)
SG (1) SG188919A1 (zh)
TW (1) TWI426072B (zh)
WO (1) WO2009115562A2 (zh)
ZA (1) ZA201006263B (zh)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR070924A1 (es) 2008-03-19 2010-05-12 Novartis Ag Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona
TR201819653T4 (tr) 2010-04-16 2019-01-21 Novartis Ag Karaciğer kanserinin tedavisinde kullanılmaya yönelik organik bileşik.
RU2012148706A (ru) 2010-04-16 2014-05-27 Новартис Аг Комбинация органичемких соединений
UY33472A (es) * 2010-06-30 2012-01-31 Novartis Ag ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?.
SG192962A1 (en) 2011-03-17 2013-09-30 Novartis Ag Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects
KR20140023358A (ko) 2011-05-19 2014-02-26 노파르티스 아게 선양 낭성 암종의 치료에 사용하기 위한 4-아미노-5-플루오로-3-[6-(4-메틸피페라진-1-일)-1h-벤즈이미다졸-2-일]-1h-퀴놀린-2-온
US20140221389A1 (en) 2011-09-15 2014-08-07 Novartis Ag Use of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one in the treatment of cancer in moderate hepatic impaired patients
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
JP2015505562A (ja) 2012-01-31 2015-02-23 ノバルティス アーゲー Ｒｔｋ阻害剤と抗エストロゲン剤との組合せ、およびがん治療のためのその使用
US20150202203A1 (en) 2012-07-11 2015-07-23 Novartis Ag Method of Treating Gastrointestinal Stromal Tumors
WO2014058785A1 (en) 2012-10-10 2014-04-17 Novartis Ag Combination therapy
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
EP3116909B1 (en) 2014-03-14 2019-11-13 Novartis Ag Antibody molecules to lag-3 and uses thereof
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
WO2016145102A1 (en) 2015-03-10 2016-09-15 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
EP3317301B1 (en) 2015-07-29 2021-04-07 Novartis AG Combination therapies comprising antibody molecules to lag-3
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
CN108025051B (zh) 2015-07-29 2021-12-24 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
EP4046655A1 (en) 2015-11-03 2022-08-24 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1317442T3 (da) 2000-09-11 2006-02-13 Chiron Corp Quinolinonderivater som tyrosinkinaseinhibitorer
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
KR20050037585A (ko) 2002-08-23 2005-04-22 카이론 코포레이션 벤지미다졸 퀴놀리논 및 그들의 사용
US20050256157A1 (en) 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
JP2006511616A (ja) * 2002-11-13 2006-04-06 カイロン コーポレイション 癌の処置方法およびその関連方法
CN100377709C (zh) * 2002-11-13 2008-04-02 希龙公司 受体酪氨酸激酶抑制剂的制药用途及相关检测方法
JP4890255B2 (ja) * 2003-11-07 2012-03-07 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 改良された薬物特性を有するキノリノン化合物の薬学的に受容可能な塩
WO2005082340A2 (en) * 2004-02-20 2005-09-09 Chiron Corporation Modulation of inflammatory and metastatic processes
DK1845990T3 (da) * 2005-01-27 2012-01-02 Novartis Vaccines & Diagnostic Behandling af metastaserede tumorer
US20110178097A1 (en) * 2005-05-23 2011-07-21 Novartis Ag Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
MY148529A (en) 2005-11-29 2013-04-30 Novartis Ag Formulations of quinolinones
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
AR070924A1 (es) 2008-03-19 2010-05-12 Novartis Ag Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona

Also Published As

Publication number Publication date
TWI426072B (zh) 2014-02-11
EP2257544A2 (en) 2010-12-08
IL208020A0 (en) 2010-12-30
US20110021536A1 (en) 2011-01-27
CN101970425A (zh) 2011-02-09
MA32230B1 (fr) 2011-04-01
MX2010010152A (es) 2010-10-25
SG188919A1 (en) 2013-04-30
NZ587829A (en) 2012-08-31
AU2009227003A1 (en) 2009-09-24
WO2009115562A2 (en) 2009-09-24
HK1147492A1 (zh) 2011-08-12
EP2257544B1 (en) 2014-12-03
MY150554A (en) 2014-01-30
CL2009000651A1 (es) 2010-07-19
AU2009227003B2 (en) 2013-03-14
NZ600887A (en) 2013-10-25
WO2009115562A3 (en) 2009-11-26
AR070924A1 (es) 2010-05-12
CO6321253A2 (es) 2011-09-20
ZA201006263B (en) 2011-05-25
PH12012502569A1 (en) 2015-09-21
TW201000463A (en) 2010-01-01
RU2497820C2 (ru) 2013-11-10
PH12012502568A1 (en) 2014-10-27
BRPI0909762A2 (pt) 2018-04-03
KR20100137517A (ko) 2010-12-30
JP2011515370A (ja) 2011-05-19
CN101970425B (zh) 2014-04-16
RU2010142396A (ru) 2012-04-27
US8563556B2 (en) 2013-10-22
ECSP10010555A (es) 2010-11-30
CA2718076A1 (en) 2009-09-24

Similar Documents

Publication Publication Date Title
PE20091628A1 (es) Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona
PE20171241A1 (es) Terapias de combinacion para el tratamiento de canceres
CU20120169A7 (es) Compuestos pirimidinílicos como inhibidores de la cinasa atr
PE20120083A1 (es) Sal monotosilato del compuesto 2-metil-2-[4-(3-metil-2-oxo-8-quinolin-3-il-2, 3-dihidro-imidazo-[4,5-c]-quinolin-1-il)-fenil]-propionitrilo en su forma cristalina a
PE20170146A1 (es) Sales cristalinas de (s)-6-((1-acetilpiperidin-4-il)amino)-n-(3-(3,4-dihidroisoquinolin-2(1h)-il)-2-hidroxipropil)pirimidino-4-carboxamida
PH12016500024A1 (en) Bromodomain inhibitor
MX2015011955A (es) Lipidos y composiciones de lipidos para el suministro de agentes activos.
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
MX2015012005A (es) Inhibidores de bromodominio.
PE20170312A1 (es) Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso
CL2014001060A1 (es) Compuestos derivados de aril-quinolina; proceso de obtencion; composicion farmaceutica que los comprende y uso en el tratamiento o profilaxis de la diabetes tipo 2, la aterosclerosis, cancer, entre otras enfermedades.
CL2009000727A1 (es) Compuestos derivados de n-hidroxi-3-fenilprop-2-enemida y n-hidroxi-3-fenilpropanamida sustituidos; inhibidores de la enzima desacetilasa; su composicion farmaceutica; utiles en el tratamiento del cancer, tumores, psoriasis, alzheimer, entre otras.
PH12015501088A1 (en) Dimeric compounds
GEP20186876B (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
CL2008002809A1 (es) Compuestos derivados de cianoisoquinolina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una adiccion a las drogas, en el tratamiento de un trastorno neurodegenerativo, como alzheimer, parkinson, demencia, entre otros.
MX364649B (es) Composición antimicrobiana.
CL2014002181A1 (es) Entidad quimica derivada de pirazolopirimidina, inhibidora de la enzima activadora de ubiquitina; forma 1 cristalina anhidra; forma 2 cristalina monohidratada; composicion farmaceutica; metodo para tratar el cancer; y uso para el tratamiento de cancer de pulmones, cancer de ovarios, cancer de colon, cancer de mama o linfoma.
MX347858B (es) Composición antimicrobiana.
EA201591649A1 (ru) Составы с органическими соединениями
MX347389B (es) Composicion antimicrobiana.
MX343517B (es) 2,4 pirimidinadiaminas sustituidas para su uso en lupus discoide.
PH12015500399A1 (en) Azaindolines
PH12015500185A1 (en) Azaheterocycles as bir2 and/or bir3 inhibitors
MX2015012386A (es) Inhibidores de la cinasa cdk9.
MX2015012153A (es) Inhibidores de la quinasa pirrolopirimidina cdk9.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed